Table 4

Clinical Outcomes Stratified by Gender and Stent Type

SESBMSSES vs. BMS
OutcomeMen (n = 629)Women (n = 249)p ValueMen (n = 622)Women (n = 248)p ValueMen p ValueWomen p Value
At 30 days (cumulative)
 Death, n (%)0 (0.0)1 (0.4)0.111 (0.2)0 (0.0)0.520.310.31
 Myocardial infarction, n (%)19 (3.0)3 (1.2)0.128 (1.3)8 (3.2)0.060.030.12
 Q-wave5 (0.8)1 (0.4)0.521 (0.2)0 (0.0)0.520.100.31
 Non–Q-wave14 (2.2)2 (0.8)0.157 (1.1)8 (3.2)0.030.120.05
 Target vessel revascularization, n (%)5 (0.8)1 (0.4)0.522 (0.3)0 (0.0)0.370.260.99
 Major adverse cardiac events, n (%)19 (3.0)4 (1.6)0.239 (1.4)8 (3.2)0.080.060.002
 Stent thrombosis, n (%)3 (0.5)1 (0.4)0.881 (0.2)0 (0.0)0.520.320.31
At 1 year (cumulative)
 Death, n (%)2 (0.3)2 (0.8)0.333 (0.5)1 (0.4)0.870.640.56
 Myocardial infarction, n (%)23 (3.7)6 (2.4)0.3415 (2.4)15 (6.1)0.0070.190.04
 Q-wave7 (1.1)1 (0.4)0.312 (0.3)1 (0.4)0.850.090.99
 Non–Q-wave16 (2.5)5 (2.0)0.6313 (2.1)14 (5.7)0.0060.580.03
 Stent thrombosis, n (%)4 (0.6)1 (0.4)0.672 (0.3)3 (1.2)0.110.410.31
 Target lesion revascularization, n (%)27 (4.3)10 (4.1)0.86132 (21.5)45 (18.3)0.36<0.0001<0.0001
 Target vessel revascularization, n (%)35 (5.6)17 (6.9)0.47147 (23.9)50 (20.4)0.33<0.0001<0.0001
 Major adverse cardiac events, n (%)48 (7.7)20 (8.1)0.87143 (23.1)55 (22.3)0.94<0.0001<0.0001

Abbreviations as in Table 1.